Treatment News : FDA Analysis: Abacavir Doesn't Increase Heart Attack Risk

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » August 2012

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


August 30, 2012

FDA Analysis: Abacavir Doesn't Increase Heart Attack Risk

There is no association between the use of ViiV Healthcare’s abacavir—found in Ziagen, Epzicom and Trizivir—and heart attack risk, according to an analysis conducted by the U.S. Food and Drug Administration (FDA) published ahead of print in the Journal of Acquired Immune Deficiency Syndromes (JAIDS). The FDA’s analysis of 26 clinical trials challenges the results of other studies in which abacavir was linked to an increased risk of heart attacks. In the studies reviewed by the FDA, which involved nearly 10,000 people who received HIV treatment between 1996 and 2010, 0.48 percent of those using abacavir-containing regimens experienced a heart attack, compared with 0.46 percent of those using abacavir-free regimens. This difference, the FDA authors concluded, was negligible and not statistically significant. The final results published in JAIDS are similar to those of a preliminary analysis presented by the FDA at the 18th Conference on Retroviruses and Opportunistic Infections (CROI) in February 2011.
To read the JAIDS paper (paid subscription required), click here.
To read coverage of the preliminary results shared at the 18th CROI, click here.

Search: hiv, fda, abacavir, epzicom, ziagen, heart attack, myocardial infarction, mi

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.